header logo image


Page 19«..10..18192021..3040..»

Archive for the ‘Personalized Medicine’ Category

Global Genomics in Cancer Care Market Professional Research By Regions, Types and Analysis of Key Players- Research Forecasts to 2027 – Daily Research…

Sunday, July 12th, 2020

Genomics in Cancer Care Market Analysis report studies latest market trends, development aspects, market gains and market scenario during the forecast period.

Latest Report published by Reportspedia titled: Global Genomics in Cancer Care Market Analysis report studies latest market trends, Market Share, development aspects, market gains and market scenario during the Forecast period 2019-2027. This study gives a comprehensive and detailed analysis of current and future 5-6 years market analyzed data of major players demanding on global market. The report explores key statistics on the Genomics in Cancer Care market status of the global and united states major industry players in detail.

Get Full Sample Report Including The In-depth Details: @ https://www.reportspedia.com/report/life-sciences/2015-2027-global-genomics-in-cancer-care-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/58342#request_sample

The Major Players Operating In Genomics in Cancer Care Market:

GE HealthcareBio-Rad LaboratoriesRoche DiagnosticsSigma AldrichPerkin ElmerAffymetrixIllumina IncAgilent TechnologiesCancer Genetics IncQiagen

It gives an detailed overview of the market, current trends, future 6 YEAR roadmap, Market challenges, industry environment, and also describes the industry chain structure & opportunities in the current market. This report Provides in-depth analysis of the scope of current and future market including the major factors such as Revenue forecast, company share, competitive landscape, growth factors, and trends, SWOT analysis i.e. Strength, Weakness, Opportunities, and Threat to the industry. In addition, this report introduces market competition status among the merchants and company outline, besides, market demand analysis and value chain features are covered in this report.

Note: Upto 30% Discount On 2020 Reserch Report

Ask For Discount: https://www.reportspedia.com/discount_inquiry/discount/58342

Significant Features Of Genomics in Cancer Care Report: :

Continue..

Customization Avaliable

Do you want any other requirement or customize the report, Do Inquiry Here: https://www.reportspedia.com/report/life-sciences/2015-2027-global-genomics-in-cancer-care-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/58342#inquiry_before_buying

Global Genomics in Cancer Care Market Split By Product Type And Applications :

By Type:

InstrumentsConsumablesServices

By Application:

DiagnosticsPersonalized MedicineDrug DiscoveryDevelopmentResearch

Genomics in Cancer Care Market Report Scope:

Table of Contents

Global Genomics in Cancer Care Market Research Report 2020 2027

For more Information or Browse the complete report @ https://www.reportspedia.com/report/life-sciences/2015-2027-global-genomics-in-cancer-care-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/58342#table_of_contents

Read the rest here:
Global Genomics in Cancer Care Market Professional Research By Regions, Types and Analysis of Key Players- Research Forecasts to 2027 - Daily Research...

Read More...

Personalized Medicine Market Size By Types, By Application, By Region, And Forecast 20202027 – Owned

Sunday, July 12th, 2020

New Jersey, United States,- The Personalized Medicine Market report upholds the future market predictions related to Personalized Medicine market size, revenue, production, Consumption, gross margin, and other substantial factors. It also examines the role of the prominent Personalized Medicine market players involved in the industry including their corporate overview. While emphasizing the key driving factors for the Personalized Medicine market, the report also offers a full study of the future trends and developments of the market.

The recently documented report on the Personalized Medicine market is a detailed analysis of this business landscape and contains important details regarding the present market trends, current revenue, market size, industry share, periodic deliverables, alongside the profit anticipation and growth rate registered during the estimated timeframe.

A thorough inference pertaining to the performance of the Personalized Medicine market over the forecast period, along with the key factors driving the market growth is enclosed in the report. It also delivers information about the market dynamics and focusses on the challenges encountered by the business vertical while providing a brief about the growth opportunities prevailing in the market over the analysis timeline.

Key highlights of the Personalized Medicine market report:

The essence of the regional bifurcation of the business sphere presented in the report:

Top key players of industry are covered in Personalized Medicine Market Research Report:

Personalized Medicine Market Classification by Types:

Bytype1

Personalized Medicine Market Size by End-user Application:

Byapplication1

Additional insights about the competitive landscape of the Personalized Medicine market:

Factors defining the competitive landscape included in the report are:

The Personalized Medicine market report encompasses a comprehensive analysis of the key facets including market concentration ratio.

The objective of the Personalized Medicine Market Report:

Cataloging the competitive terrain of the Personalized Medicine market:

Unveiling the geographical penetration of the Personalized Medicine market:

The report of the Personalized Medicine market is an in-depth analysis of the business vertical projected to record a commendable annual growth rate over the estimated time period. It also comprises of a precise evaluation of the dynamics related to this marketplace. The purpose of the Personalized Medicine Market report is to provide important information related to the industry deliverables such as market size, valuation forecast, sales volume, etc.

Major Highlights from Table of contents are listed below for quick lookup into Personalized Medicine Market report

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Our Trending Reports

Wireless EV Charging Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Personalized Medicine Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Smart Robot Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

IOT in Elevators Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Narrowband IoT Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read more:
Personalized Medicine Market Size By Types, By Application, By Region, And Forecast 20202027 - Owned

Read More...

Building on Strengths in Aging Care – The Lane Report

Sunday, July 12th, 2020

By Dianne H. Timmering

HEALTH CARE

COVID-19 has changed everything.

After any war, cities need to be rebuilt, national economies restored, global communities re-established. Due to the pandemic shutdown, Louisville Metro may face a $30-40 million deficit. And now after the recent public protests, that price tag may be even higher. The city has assets and aspirations, however.

Among those aspirations is Louisvilles goal to become the aging innovation capital of the world. The aging-care segment of health care is worth about $8 trillionmeaning that if Louisville captured even 1% of the market, it would represent some $80 billion annually for the city.

Some of that is already happening, but creating a collaborative economic ecosystem netting just 1% of aging care would mean a cash flow of more than a third of Kentuckys current gross domestic product (GDP), creating significant opportunity. A flourishing Louisville aging-care cluster could rebuild a strong economy by supplying the rapidly growing new demands and needs of an aging world.

As the source of more than 40% of Kentuckys tax revenues, Louisvilles economic importance to the state is already great. Yet, imagine what becoming a major aging innovation capital could be worth to a city in financial distress. A health care renaissance could resolve economic burdens that we havent seen since the Great Depression.

In times of crisis, you go to your strengths and we have that strength in health care aging innovation, said Mary Ellen Wiederwohl, chief of Louisville Forward. And while U.S. cities begin the recovery from both a health pandemic and a reckoning from institutional racism in this country, we need to think about how were going to build back our economy in a way that benefits all of our residents. By going to one of our core strengths, we have a greater opportunity to do so.

Anthony Ellis, the Kentucky Cabinet for Economic Developments acting executive director of KY Innovationthe agencys entrepreneurship officeunderscored the importance of Louisvilles efforts.

We are extremely excited about Louisvilles continued growth in the entrepreneurship and startup sector. With strong leadership in its support organizations like LHCC (Louisville Healthcare CEO Council) and the RISE office (a nonprofit that supports refugees and immigrants), a vibrant and active sector, and collaborative mentors, Louisville is primed for explosive growth as we head into this economic recovery. Aging care is a clear sector for our startup community to target, as Louisville and the commonwealth generally have a robust health care and long-term care industry, and have been a driving force in developments in these segments, said Ellis, who is also the Cabinets general counsel.

As a cabinet, we work to grow jobs, recruit talent and generate business investment in all 120 Kentucky counties. When our largest city and so many of its community leaders come together to collaborate on a project like this, its exciting for the commonwealth as a whole. We at the state are committed to this effort and supporting these innovation activities.

Gov. Andy Beshear is also behind Louisvilles initiative.

The pandemic and recent protests have created both urgency and opportunity in ensuring we build a more equitable future for all Kentuckians, including our older citizens. The partners working to grow Louisville as an aging-care hub are exactly who youd want on your team, Gov. Beshear said. We support the aging-care vision for Louisville and consider the commonwealth a committed partner. Whether in our recruiting, marketing, helping existing businesses grow or by partnering to create a strong startup and innovation culture, Team Kentucky is working toward that same future.

Health care has changed. Health care will change. Leaders of a health-care consortium in the city of bourbonism (a term the city has created to define the tourism draw of its many bourbon-related sites) and horses believe aging innovation can be the front-line of its future. They see it creating trends to solve and fill gaps, evolving solutions to needs and demands in a new health care world while also improving wellness and driving new care modelsif Louisville can create the framework to support innovation.

There are significant building blocks and cornerstones, some new, some having emerged over years:

The Microsoft Digital Alliance Partnership and Future Work Initiative in partnership with the city, the University of Louisville, and the Brookings Institution was created in 2019 to build a regional digital ground zero for artificial intelligence (AI) and the internet of things (IoT).

Much of the thrust is centered on digital transformation of the workforce for a tech future. It is no coincidence that Louisvillehome to multiple champions of aging health care, from insurance to post-acute care to hospiceattracted this partnership. Together, all the above could be a natural alignment to lead aging innovation.

We are grateful to Microsoft. They see an opportunity that has some unique advantages to be driving innovation in the data economy, which is connected to our aging cluster, said Ben Reno-Weber, director of the Microsoft Future of Work Initiative. Louisville, like no other city, has a reservoir of data resources that can trace data across an entire companys lifecycle. Theres not a place where you can do that everywhere.

Reno-Weber urges a reframing of how to see data. He imagines shifting its current view from that of a cost center into an integral part of doing business, especially with the aging silver tsunami now arriving.

Once we build that infrastructure, he said, because health care concentration is such an important part of our industry, success in the data economy is not about the technical shift but a cultural one. If a company in the health care space is going to be successful, it must change the way it sees data as a corporate asset.

The aggregated power of the Big 12 companies now known as the Louisville HealthCare CEO Council (LHCC):

Some key partnerships are evolving within the LHCC, whose companies (with $100 billion in revenue) represent the length, breadth and complexities of the health care ecosystem, from payor to provider to those on the front lines of solving health care problems. Those initial discovery labs will likely evolve now based on the new normal, such as the need for elevated infection control, the emergence of telemedicine, and a first line of defense against a second COVID-19 wave.

Post-COVID aging innovation solutions will center around the need for intense infection control, says Dr. Arif Nazir, immediate past president of The Society for Post-Acute and Long-Term Care Medicine and chief medical officer at Signature Healthcare, a LHCC member.

We all need to be better stewards of infection control patterns, Nazir said. Just think about whats possible here with new competencies in infection control like face recognition and the ability to trace ones steps and who used the sink last, how long hands were washed.

With one in five Americans soon to be 65 or older, LHCC is stepping into the leadership limelight in aging innovation with its upcoming Global Healthcare Summit, now scheduled for Sept. 2-3, 2020. One of the goals of the summit is for national and world leaders and communities to take note: Louisville is solving global problems and community health issues.

International pharma is focusing on Louisville and the power of real data-sharing. Pfizer Inc. and the University of Louisvilles Division of Infectious Diseases have an established history of collaboration. Their synergistic alliance now will become the basis for one of the first of eight adult population research centers being placed globallyand the only one in North America. UofL will play a significant role in epidemiological research related to vaccine-preventable diseases affecting adults, including the elderly, a recent UofL news release states.

The reason for the selection, Reno-Weber said, is that nine hospitals that treat in Louisville are willing to share their data. At least one of the senior physicians was trained at CERID (The Center of Excellence for Research in Infectious Diseases).

Aging2.0 partnership and relocation to the city:

Anticipating the next chapter for boomers, Aging2.0 was founded in 2012 on the West Coast to address the need for aging innovation with a public-private approach and international reach that has grown to 40,000 innovators across 31 countries, with a chapter network that spans 120 cities and 700 events around the world.

Aging2.0 moved its headquarters to Louisville in May, announcing a strategic alliance with LHCC that enhances the citys recognition as a global epicenter.

Ecosystem emerged from Humana

The citys culturally rich aging-care hegemony has its roots in Humanas early history in the 1960s, when it became the largest nursing home company in the U.S., then transformed into one of the largest hospital companies, and next launched its own health insurance plan in the 1980s. As the American health care system changed, so did Humana. The companys alumni spun proficiencies they developed there into new companies that today are an ecosystem.

When an industry has thus chosen a locality for itself, the great 19th-centuryeconomist Alfred Marshall wrote, it is likely to stay there long, so great are the advantages which people following the same skilled trade get from near neighborhood to one another. The mysteries of the trade become no mysteries; but are as it were in the air, and children learn many of them unconsciously.

Louisville might next evolve into a driver of expertise in staffing advancements; cures; the tech embrace of data realities; precision medicine; virtual care; the social determinants of outcomes; and the power of the one-on-one to deliver personalized health care that has never existed before.

LHCC members want real data share opportunity that can link with and push statewide advances out through the university system. They imagine Louisville being the pandemic crusader and COVID-19 killer for the worldespecially as the leader in aging innovation, saving the most vulnerable among us.

Its that cultural piece that is potentially powerful, Reno-Weber said. Either we take advantage of it or we dont.

Louisville still needs money and trust

The finances of funding startup innovation and sustaining those start-ups through pivots and evolution to achieve sustainability are complex.

Entrepreneurs do, indeed, raise real money locally. In 2019, $70 million in capital was invested in Louisville. Investors often want the company to remain local for obvious reasons: community investment, access to the build, future growth implications, proximity to health care or pilot companies. They want companies to access ongoing local support and the navigational advantages of newer organizations like Louisville Entrepreneurship Acceleration Partnership (LEAP), and stalwarts like XLerate Health. There is growing a sense that having the money in Louisville and keeping it here is not the disadvantage that it may have once been.

But those involved in the Kentucky funding community have long said there still is not enough of it. There are, indeed, a lot of angel and venture groups out there and a robust smaller investment category for super start-ups for $1 million or less, says Gill Holland, a community leader and developer who launched reinvigoration of the NuLu area just east of downtown. What were lacking is the $1 to $5 million for a $10 million raise. We need to get better at attracting out-of-town money.

One local innovator, for example, received an investment from a Columbus, Ohio, incubator but then had to move his company there. And other startups dont need large amounts of money, Holland said, because theyre more centered around the ones and zeros of computer programming.

What Louisville lacks and does need if it is to attract and encourage creative entrepreneurshipespecially when solving for the aging care and innovation gapsare the bigger dollars of serious equity investment and the funding that can take a solution to manufacturing and be able to see it through an FDA approval process, Holland said.

Such a robust investment community could support, for example, an innovator like Crestwood, Ky.-based Liberate Medical, which is being recognized for its external electrical neuromuscular ventilator technology, which can speed patient liberation from mechanical ventilation. Due to the increased need for ventilators caused by the COVID-19 pandemic, the technology now has the sudden opportunity to be fast-tracked by the Food and Drug Administration (FDA).

Kelby Price, executive director of Venture Capital at Kentucky Science and Technology Corp., agrees.

Growing Series A investment activity will require more talent, more new companies or starts, and more successful exits, Price said. Simply said, in order to do it here, the source of the deal or local investors needs to be successful.

Instead, says Larry Horn, director of LEAP, there is a sucking sound from the venture capital community outside of the state, looking to take away companies with good ideas.

LHCC aims to reverse that financial draw by creating not just opportunity for aging care-based innovation but new capital dollars from pre-seed to Series B. In 2019 it launched the LHCC Strategic Investment Fund in partnership with an already-established investment committee. The funds goal is to deploy the type of dollars that can scale innovation and generate financial momentum and wider revitalization.

According to Horn, Louisville investors can protect their investment and its value by maintaining it right in the city where its being developed, grown and piloted. A lead advantage for Louisville, he argues, is that the communitys density of knowledge is offering more than just money but mentorship and inroads to potential customers.

Louisvilles health care industry offers comparative advantages to leverage early-stage companies faster: validating that a problem has a possible business solution, pilot-testing strategically with first customers, a willingness to assume the risk of trying new things, and the market in which to do it.

There are a lot of ingredients there, Price said.

Holding them together will require a culture of trust, which is necessary in order to believe that collaboration can create more value, not competition. Potential impediments to success could be inadequate trust among the Big 12 LHCC members on the data share; navigating 12 unique corporate cultures for early investment dollars; a well-developed pilot that never lifts off; or a stalled opportunity in early adoption phase due to compliance or other legal burdens in an over-regulated HIPAA nation.

Solving for the new normal

Now is the time for Louisville to take the lead in AI based solutions, LHCC member Nazir said, including the automation of wearables so when a doctor logs in, he or she already has 1,000 readings from the pulse rate and we can then start to see trends in their health.

By automating data gathering for significant health determinants, personalized health care evolves. It allows matching community resources with the background of the patient, enabling clinicians to offer better patient care and services.

With wearables, Nazir said, there are more eyes on his patientsdigital eyes that do not tire. And he can focus on responding to needs better and faster while being able to adapt care plans or pathways.

He and other LHCC members see a health care that could involve the following:

Wearablesa new kind of technology that fulfills the need for a better understanding on what is going on in the patients body. For instance, simple matters like how any times a patient is turned in a hospital bed can be significant. Human resources make it impossible for a one-on-one clinical patient ratio but with wearables and real-time data, might feed AI for a type of robotic nurse.

Personalized medicine through geneticsgiving the patient what they need via a personalized medicine, which links to the data-share opportunity between the Big 12 and the citys digital alliance with Microsoft. The COVID-19 experience is accelerating the arrival of a new landscape of digital medicine that the world is increasingly ready for.

Technology with a human touchTelemedicine and broader-based telehealth solutions are all the rage with their urgent adoption due to the dual needs of preventing transmission and getting care to elders who are the most vulnerable to the coronavirus. But it cannot replace the care given face-to-face. While doctors and clinicians are embracing it for many reasons, social distancing is still considered a temporary practice, and care delivery remains a very organic relationship.

Specialties will begin to expandTechnology is creating an opportunity to push more specialist care out into the system. The medical community already is curious after this springs telehealth regulatory waivers to see where health care licensing rules go, as well as interstate commerce of physicians and specialists across state lines.

Creativity in financial controlsPayors are embracing technology for prevention, compassion and lowered costs. Insurance is granting more flexibility of services. Rebranding American health care, with new codes, new waivers and new requests will become a necessity for driving quality care into rural areas, for preventing COVID-19 for patients and staff alike, and making distance care an option.

Filling the need for a new normal

The new normal almost forces a new philosophical framework overlay that has ruled this country since its foundational pillar of capitalism and individualism.

Deficits at the city, county and state levels will demand a new economy with new economic realities. Meeting budgetary shortfalls and bankruptcy threats may be solved by the density of health care knowledge right in the heart of Louisvilleif pooled into a post-COVID strategy to revitalize an economy that drives job growth, tax revenues and repopulates hope.

Greater Louisvilles health care leaders think they have the goods, the expertise, the brilliance, the industry respect, the global outreach and the existing infrastructure to figure this out. And a billion people need it.

Dianne H. Timmering is a correspondentfor The Lane Report. She can be reachedat [emailprotected]

Originally posted here:
Building on Strengths in Aging Care - The Lane Report

Read More...

‘MasterChef’s Resident KatyCat Reece Was Eliminated Tonight & Is Somebody Cutting Onions? – Pedestrian TV

Sunday, July 12th, 2020

Well folks, I guess we can just endMasterChefright here because sweet angel boyReece Hignellhas officially left the kitchen and to quoteMy Chemical Romance:Im not okay.

Maybe I had a soft spot for him as the shows token vegan and token KatyCat, but simply cannot stress how hard I was rooting for him.

But unfortunately, no matter how hard I try, I am notMelissa Leong and therefore, did not have the power to save our beloved Reece tonight.

Thankfully, he had a good run and even got to meet his idolKaty Perryat one point this season.

Tonights episode saw the remaining contestants battle it out presenting a four-course meal for some of the countrys greatest chefs.

Ultimately, it came down to Reece andCallum, who served up vegetables and dessert respectively.

But unfortunately for Reece, the judges felt like he didnt quite try hard enough, while Callum tried a little ~too~ hard.

When the decision was handed down, poor, sweet Reece was sent packing.

Fans were understandably heartbroken.

We simply cannot handle this.

Justice for our OG KatyCat.

Oh, and while were at it, give him a TV show too.

Seriously, Im sobbing. I cannot handle this.

I know, I know, every elimination when it gets down to the final few is tough. But GOD, I didnt expect it to be THIS emotional.

All of the MasterChef contestants are just so wholesome, at least when aBachiecontestant gets the boot theyve usually done something to warrant it. But all of these people are just trying to make tasty food! Cant they all win? Give them all a prize! Participation trophies for all!

Visit link:
'MasterChef's Resident KatyCat Reece Was Eliminated Tonight & Is Somebody Cutting Onions? - Pedestrian TV

Read More...

Decoding the Future Trajectory of Healthcare with AI – Digital Market News

Sunday, July 12th, 2020

Artificial Intelligence (AI) is getting increasingly sophisticated everyday in its application, with enhanced efficiency and speed at a lower cost. Every single sector has been reaping advantages of AI recently. The Healthcare industry isnt any exception. Here is decoding the future trajectory of healthcare with AI.

- Advertisement -

The impact of artificial intelligence in the healthcare industry through machine learning (ML) and natural language processing (NLP) is transforming care delivery. Additionally, patients are expected to achieve relatively high access to their health-related information than before through various applications such as for instance smart wearable devices and mobile electronic medical records (EMR).

The personalized healthcare will authorize patients to just take the wheel of their well-being, facilitate high-end healthcare, and promote better patient-provider communication to underprivileged areas.

- Advertisement -

For instance, IBM Watson for Health is helping healthcare businesses to apply cognitive technology to supply a vast amount of power diagnosis and health-related information.

In addition, Googles DeepMind Health is collaborating with researchers, clinicians, and patients to be able to solve real-world healthcare issues. Additionally, the company has combined systems neuroscience with machine understanding how to develop strong general-purpose learning algorithms within neural networks to mimic the mind.

Companies are working towards developing AI technology to resolve several existing challenges, particularly within the healthcare space. Strong give attention to funding and starting AI healthcare programs played a substantial role in Microsoft Corporations decision to launch a 5-year, US$ 40 million program referred to as AI for Health in January 2019.

The Microsoft program will use artificial intelligence tools to resolve some of the greatest healthcare challenges including global health crises, treatment, and infection diagnosis. Microsoft has also ensured that academia, non-profit, and research businesses have access to this technology, technical experts, and resources to leverage AI for care delivery and research.

In January 2020, these factors influenced Takeda Pharmaceuticals Company and MITs School of Engineering to join hands for 36 months to drive innovation and application of AI in the healthcare industry and drug development.

AI applications are just centered on three main investment areas: Diagnostics, Engagement, and Digitization. With the rapid advancement in technologies. There are exciting breakthroughs in incorporating AI in medical services.

The most interesting aspect of AI is robots. Robots arent only replacing trained medical staff but in addition making them more efficient in a number of areas. Robots help in controlling the cost while potentially providing better care and performing accurate surgery in limited space.

China and the U.S. have started investing in the development of robots to guide doctors. In November 2017, a robot in China passed a medical licensing exam only using an AI brain. Also, it was the first-ever semi-automated operating robot that was used to suture blood vessels as fine as 0.03 mm.

In order to avoid coronavirus from spreading, the American medical practioners are counting on a robot that can measure the patients act and vitals. In addition, robots are also used for recovery and consulting assistance and transporting units. These robots are showcasing significant potential in revolutionizing medical procedures in the future.

Precision medicine is an emerging approach to infection prevention and treatment. The precision medication approach allows researchers and doctors to predict more accurate treatment and prevention strategies.

The advent of precision medicine technology has allowed healthcare to actively track patients physiology in real-time, take multi-dimensional data, and create predictive algorithms that use collective learnings to calculate individual outcomes.

In modern times, there has been an immense give attention to enabling direct-to-consumer genomics. Now, companies are aiming to create patient-centric products and services within digitization processes and genomics linked to ordering complex testing in clinics.

In January 2020, ixLayer, a start-up based in San-Francisco, launched one of its kind precision health testing platforms to improve the delivery of diagnostic testing also to shorten the complex relationship among physicians, precision health tests, and patients.

Personal health monitoring is really a promising example of AI in healthcare. With the emergence of advanced AI and Internet of Medical Things (IoMT), demand for consumer-oriented products and services such as smart wearables for monitoring wellbeing is growing notably.

Owing to the rapid proliferation of smart wearables and mobile apps, enterprises are introducing varied options to monitor personal health.

In October 2019, Gali Health, a health technology company, introduced its Gali AI-powered personal health assistant for people struggling with inflammatory bowel diseases (IBD). It offers health tracking and analytical tools, medically-vetted educational resources, and emotional support to the IBD community.

Similarly, start-ups are also coming forward with innovative devices integrated with state-of-the-art AI technology to contribute to the growing demand for personal health monitoring.

In modern times, AI has been found in numerous methods to support the medical imaging of all types. At present, the biggest use for AI would be to assist in the analysis of images and perform single narrow recognition tasks.

In the United States, AI is known as highly valuable in enhancing business operations and patients care. It has the greatest affect patient care by improving the accuracy of clinical outcomes and medical diagnosis.

Strong presence of leading market players in the country is bolstering the demand for medical imaging in hospitals and research centers.

In January 2020, Hitachi Healthcare Americas announced to start a brand new dedicated R&D center in North America. Medical imaging will leverage the advancements in machine learning and artificial intelligence to result in next-gen of medical imaging technology.

With plenty of dilemmas driven by the growing rate of chronic infection and the aging populace, the requirement for new innovative solutions in the healthcare industry is moving on an upswing.

Unleashing AIs complete potential in the healthcare industry is not a facile task. Both healthcare providers and AI developers together must tackle all the obstacles on the path towards the integration of new technologies.

Clearing all the hurdles will need a compounding of technological refinement and shifting mindsets. As AI trend become more deep-rooted, it is giving rise to highly ubiquitous discussions. Will AI replace the health practitioners and medical experts, especially radiologists and physicians? The reply to this is, itll increase the efficiency of the medical experts.

Initiatives by IBM Watson and Googles DeepMind will soon unlock the critical answers. However, AI aims to mimic the mind in healthcare, human judgment, and intuitions that cant be substituted.

Even though AI is augmenting in existing capabilities of the industry, it really is unlikely to completely replace human intervention. AI skilled forces will swap only people who dont wish to embrace technology.

Healthcare is a dynamic industry with significant opportunities. However, uncertainty, cost concerns, and complexity are rendering it an unnerving one.

The most useful opportunity for healthcare in the near future are hybrid models, where clinicians and physicians will be supported for treatment planning, diagnosis, and pinpointing risk facets. Also, with an increase in the number of geriatric population and the rise of health-related concerns across the globe, the over all burden of disease management has augmented.

Patients are also expecting better treatment and care. Due to growing innovations in the healthcare industry with respect to improved diagnosis and treatment, AI has gained consideration among the patients and health practitioners.

In order to develop better medical technology, entrepreneurs, healthcare service providers, investors, policy developers, and patients are coming together.

These facets are set to exhibit a brighter future of AI in the healthcare industry. It is very likely that there will be widespread use and massive advancements of AI integrated technology in the next several years. Moreover, healthcare providers are anticipated to invest in sufficient IT infrastructure solutions and data centers to support new technological development.

Healthcare companies should continually integrate new technologies to build strong value also to keep the patients attention.

-

The insights presented in the article are derived from a recent study on Global Artificial Intelligence In Healthcare Market by Future Market Insights.

Abhishek Budholiya is really a tech blogger, digital marketing pro, and contains contributed to varied tech magazines. Currently, as a technology and digital branding consultant, he offers his analysis on the tech general market trends landscape. His forte is analysing the commercial viability of a brand new breakthrough, a trait you can view in his writing. When he is maybe not ruminating about the tech world, he is able to be found playing ping pong or chilling out with his friends.

See the original post here:
Decoding the Future Trajectory of Healthcare with AI - Digital Market News

Read More...

Researcher leads international study of patients at risk of heart failure and death – UCalgary News

Saturday, July 11th, 2020

Heart failure impacts between three to four per cent of the general population. While commonly related to heart attacks it can also be due to a condition called dilated cardiomyopathy (DCM), a disease characterized by an enlarged and weak heart muscle that cant efficiently pump blood.

An international, multi-centre study led by Dr. James White, MD, a clinician and researcher at the University of Calgarys Cumming School of Medicine (CSM), has revealed magnetic resonance imaging (MRI) can be used to predict major cardiac events for people diagnosed with DCM.

Whites study, published in Circulation Cardiovascular Imaging, confirms about 40 per cent of patients with DCM have scarring patterns on their heart muscle which can be seen with MRI. These patterns are associated with higher risk of future heart failure admissions, life-threatening heart rhythms and death.

The study, which was the largest ever conducted using MRI in patients with DCM, also shows that cardiac MRI can play an important role in guiding the care of individual patients with heart failure, an approach called personalized medicine. The results of this study could lead to trials looking at how patients at higher risk may benefit from more intensive treatments. White says that treating patients with DCM is challenging because there is a lack of understanding into what causes the disease and why patients respond differently to the available treatments.

We have tended to think of dilated cardiomyopathy as one type of heart disease and that all patients should respond the same way, but we are learning that it is a collection of disease states that affect each patient differently, says White, explaining those that dont respond well to treatments are more prone to cardiac arrest, which kills about 35,000 Canadians annually.

The purpose of our study was to see if we could find individual patient features that can help us prescribe life-saving therapies, such as the ICD (implantable cardioverter defibrillator).

White and his team assembled the MINICOR (Multimodal International Cardiovascular Outcomes Registry) group, which involves 12 centres from Canada, the United States, Spain and Italy, to provide researchers access to highly standardized data collected from patients around the world with the goal of promoting personalized care for patients with cardiovascular disease.

We can have a much greater impact on patient care and on clinical practice in general when we work together, says White The true benefit of initiatives like this is our ability to test innovative ideas quickly and show they can work in different health-care systems and patient populations. This is the unique power of multi-national collaborations.

White and his team of data scientists and students are currently tracking the health of more than 10,000 Albertans who have undergone cardiac MRI.With this data they are developing new approaches to deliver personalized risk prediction models for patients with cardiovascular disease.

Libin Institute director Dr. Paul Fedak, MD, PhD, is excited about the potential of this project and its alignment with the institutes aim to lead in the area of precision cardiovascular medicine.

These are important steps towards personalizing care decisions for individual patients, says Fedak. We are constantly being reminded that the more we know about each patient and their own disease, the better we can make decisions to improve their health.

James Whiteis a professor in the departments of Cardiac Sciences, Radiology and Medicine and a member of the Libin Cardiovascular Institute at the Cumming School of Medicine.

James White led an international study on heart failure. Here, he stands in front of the cardiac MRI machine in the Stephenson Cardiac Imaging Centre.

Britton Ledingham for Libin Cardiovascular Institute

Read the rest here:
Researcher leads international study of patients at risk of heart failure and death - UCalgary News

Read More...

Companion Diagnostics Market Insights on Scope the COVID-19 – 3rd Watch News

Saturday, July 11th, 2020

Global Companion Diagnostics Market was valued US$ 2.68 Bn in 2017 and is expected to reach US$ 10.76 Bn by 2026, at a CAGR of 18.98 % during a forecast period.

A diagnostic is a process of determining disease, condition, and illness, which clarifies a person symptoms & signs that is useful for an individuals treatment. Companion diagnostic is a medical device that provides important information required for the safety & effective use of a biological product. Companion diagnostics are majorly used in the oncology area due to the growing incidence of cancer and it improvers the focus on cancer research.

The important driving factors of the global companion diagnostics market are the rising demand for targeted therapy and the increasing prevalence of cancer. Rising awareness of personalized medicines, growing cases of adverse drug reactions, and co-development of drug & diagnostic technology is also boosting the growth market.

Request For Report sample @ https://www.trendsmarketresearch.com/report/sample/5712

Increasing demand for next-generation sequencing and emerging applications of companion diagnostics in oncology indication provides key opportunities for companion diagnostics market. However, high cost involved in the development of therapeutics & diagnostic tests, and issues related to intellectual property rights is limiting the market growth.

The assay kits & reagents segment accounted for the largest share in the market, owing to its wide range of applications in platforms such as PCR, NGS, IHC, and ISH. Polymerase chain reaction (PCR) is a method widely used in molecular biology to make many copies of a specific DNA segment and is occupied the largest share during the forecast period.

Next-generation sequencing (NGS) is the technology that is used to arrange millions of small fragments of DNA in a line at the same time NGS are capable of processing multiple DNA sequences in parallel. NGS is expected to grow at a high CAGR during the forecast period owing to the availability of next-generation sequencing at low cost, technological advancements and high prevalence of cancer cases.

The supportive government initiatives to promote precision medicine research, along with the strategic alliances between key market players for companion diagnostics test development is expected to hold the largest share in North America followed by Europe throughout the forecast period. Increasing technological advancements aimed at developing companion diagnostic tests for new indications such as neurology, infectious diseases are also expected to hold the largest share in this region. Europe is rising demand for efficiency in healthcare & strengthening healthcare system and Germany is the largest market in Europe due to the presence of major market players and growing demand for technological advancement in these regions. However, Middle East & Africa are estimated to have a limited but stable growth owing to low healthcare expenditure and demand for primary healthcare services in this region.

Key player operating in the global companion diagnostics market are Abbott Laboratories, Agilent Technologies, Inc., ARUP Laboratories, BioMrieux SA, Danaher Corporation, F. Hoffmann-La Roche AG, Illumina, Inc., Invivoscribe Technologies, Inc., MolecularMD Corporation, Myriad Genetics, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., ArcherDx, Inc., Exosome Diagnostics, Inc., NeoGenomics, Inc., MDxHealth, Inc., and NanoString Technologies, Inc.

Scope of Global Companion Diagnostics Market:

Global Companion Diagnostics Market, by Product and Service:

Assay kits & reagents

Software & service

Global Companion Diagnostics Market, by Technology:

In situ hybridization

Polymerase chain reaction

Immunohistochemistry

Next-generation sequencing

Other technologies

Global Companion Diagnostics Market, by Indications:

Oncology

Neurology

Infectious diseases

Other indications

Global Companion Diagnostics Market, by End-User:

Pharmaceutical & biopharmaceutical companies

Reference laboratories

Other end users

Global Companion Diagnostics Market, by Region:

North America

Europe

Asia-Pacific

South America

Middle East & Africa

Key Player Operating In the Global Companion Diagnostics Market:

Abbott Laboratories

Agilent Technologies, Inc.

ARUP Laboratories

BioMrieux SA

Danaher Corporation

F. Hoffmann-La Roche AG

Illumina, Inc.

Invivoscribe Technologies, Inc.

MolecularMD Corporation

Myriad Genetics, Inc.

QIAGEN N.V.

Thermo Fisher Scientific Inc.

ArcherDx, Inc.

Exosome Diagnostics, Inc.

NeoGenomics, Inc.

MDxHealth, Inc.

NanoString Technologies, Inc.

More Info of Impact Covid19 @ https://www.trendsmarketresearch.com/report/covid-19-analysis/5712

Read more from the original source:
Companion Diagnostics Market Insights on Scope the COVID-19 - 3rd Watch News

Read More...

Got $5,000? Buy Stocks in These 5 Industries Now – Motley Fool

Saturday, July 11th, 2020

This year has truly been a tale of two markets. For a five-week period in the first quarter, downside momentum in the stock market tied to the coronavirus disease 2019 (COVID-19) pandemic was unlike anything we'd ever seen before. But over the past 3.5 months, Wall Street has undertaken its strongest rally in more than two decades.

If 2020 has taught investors anything, it's the power of long-term investing and sticking with your initial investment thesis, even if some pretty big hiccups present themselves.

It's also taught investors that you don't need to be rich to become rich in the stock market. If you have $5,000 in cash at your disposal that won't be needed to pay bills or for emergencies, then you have more than enough capital to put to work in some of the fastest-growing industries in the new bull market. Here are five industries you'd be smart to consider buying into right now with $5,000.

Image source: Getty Images.

If these industries were being presented in any particular order (which they aren't), cloud computing would likely be at the top of the list. Even before COVID-19 became a serious concern, we were already witnessing a steady transition toward remote and shared-work capabilities. COVID-19 simply provided a shot in the arm to facilitate this transformation even faster. In my mind, there's little question that cloud growth should consistently remain in the double-digits on an annual basis throughout this decade.

While there are no shortage of cloud service companies to choose from, e-commerce giant Amazon (NASDAQ:AMZN) might be the preferred stock to own. Amazon Web Services (AWS) operates as an infrastructure-as-a-service player, which is a fancy way of saying that it supplies small and medium-sized businesses with the tools necessary to form the building blocks of their cloud-based platform. In just a five-quarter stretch, AWS has grown from 11% of Amazon's total sales to 13.5% of total sales, while accounting for the lion's share of its operating income during the first quarter.

Make no mistake about it, high-margin cloud sales are going to generate insane amounts of cash flow for Amazon and other cloud-service providers.

Image source: Getty Images.

If there's such a thing as a no-brainer industry to buy, it's cybersecurity. No matter how well or poorly the U.S. and global economy are performing, hackers don't take time off. This makes the hardware and subscription protection services provided by cybersecurity companies an absolute necessity. And with more businesses pushing into the cloud than ever before, there's a growing need for more sophisticated security solutions.

Here, I continue to be a fan of what Palo Alto Networks (NYSE:PANW) is doing. In recent quarters, Palo Alto has deemphasized physical firewall products in favor of higher-margin subscription and support services. This will lead to more consistent revenue recognition and should help reduce what little client churn the company is contending with. And yes, it'll help improve operating margins over the long run, too.

Palo Alto has also diversified its product offerings through numerous bolt-on acquisitions. Look for the company to continue spending aggressively on innovation and inorganic growth to improve its cloud-protection market share.

Image source: Getty Images.

The cannabis industry gets a bit of a bad rap given that the bubble finally burst in pot stocks over the past 15 months. Supply issues to our north, high tax rates in select U.S. markets, and financing concerns throughout North America have coerced caution from investors.

But this is still an industry where tens of billions of dollars in sales are conducted annually in the black market. It's expected that these illicit channels will gradually give way to legal sales over time and offer the North American marijuana industry a double-digit growth opportunity throughout much of the 2020s.

An intriguing name to consider here is Green Thumb Industries (OTC:GTBI.F). Green Thumb is a multistate operator with 48 open dispensaries and licenses to open as many as 96 stores in a dozen states. Green Thumb is currently generating about two-thirds of its revenue from higher-margin derivatives, rather than dried cannabis flower, which is a big reason it looks to be on the cusp of recurring profitability.

Furthermore, Green Thumb has established a significant presence in Illinois, which opened its doors to recreational weed sales on Jan. 1, 2020, as well as Nevada, which has the potential to lead the nation in cannabis spending per-capita by mid-decade.

Image source: Getty Images.

Another industry that looks set to come into its own is the Internet of Things (IoT). By IoT, I'm talking about wireless devices that can communicate with other wireless devices, as well as data centers. Like marijuana, IoT was hyped up too quickly in the 2010s, but has now had time to mature. This growing focus on technology making our lives easier is bound to have a positive impact on IoT companies for years to come.

The name to watch here is NXP Semiconductors (NASDAQ:NXPI), which generated almost half of its revenue last year from the automotive industry, with industrial equipment, communications, and mobile comprising the remainder of sales in 2019. In particular, NXP is a leader in self-driving and sensor equipment used in a number of newer automobiles. Between 2018 and 2021, NXP expects to have delivered a compound annual growth rate of 7% to 10% (this includes 2021 as an estimate), which is outpacing the CAGR for the IoT auto market of 5% to 7% over this same time frame.

Additionally, don't overlook other growth drivers for NXP, such as mobile payment adoption, the rollout of 5G networks, and its scalability in industrial processing applications.

Image source: Getty Images.

Last, but not least, don't forget about the personalized medicine push. Anything that caters to individual patient needs, especially during a pandemic, is likely to see demand improve significantly over the long run.

As a perfect example, take a closer look at Teladoc Health (NYSE:TDOC), which provides telemedicine visits for patients. Not only are these virtual visits critical during the pandemic to ensure that sick people remain in their homes, but it's a considerably more convenient method of arranging a consultation with a physician. It also doesn't hurt that telemedicine visits tend to be cheaper for insurance providers.

During the pandemic-impacted first quarter, Teladoc reported an absurd 92% uptick in virtual visits, with its paying membership increasing by 61% to 43 million people in the United States. Visit-fee-only access increased by a whopping 89%, as well. Though there's little question that Teladoc Health will continue to lose money in the near-term as it enhances its platform and makes complementary acquisitions, it clearly has the tools necessary to become a major player in personalized health over the next decade.

See the article here:
Got $5,000? Buy Stocks in These 5 Industries Now - Motley Fool

Read More...

Global Microbiome Sequencing Market 2020 Business Outlook with Pandemic Scenario Analysis and Forecast 2026|Oxford Nanopore Technologies; BaseClear…

Saturday, July 11th, 2020

Global microbiome sequencing marketis expected to rise to an estimated value of USD 3455.33 million by 2026, registering a healthy CAGR in the forecast period of 2019-2026. This rise in market value can be attributed to the focus of various researchers on utilization of this technology in the development of personalized medicine and dietary applications.

The study of Microbiome Sequencing report helps businesses to define their own strategies about the development in the existing product, modifications to consider for the future product, sales, marketing, promotion and distribution of the product in the existing and the new market. The research and analysis performed in this report with the consistent knowledge gives businesses clear idea of what is already available, what the market expects, the competitive environment, and what can be done to outshine the competitor. This research study also helps businesses to understand the various drivers and restraints impacting the market during the forecast period.

Ask For Complimentary Sample PDF| Request Athttps://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-microbiome-sequencing-market

Few of the major competitors currently working in the global microbiome sequencing market areBIOLOG; Cosmosid Inc; Illumina, Inc.; Metabiomics Corp.; Oxford Nanopore Technologies; BaseClear B.V.; BGI; BioMathematica; Charles River; CoreBiome, Inc.; Clinical-Microbiomics A/S; Diversigen; Eurofins Scientific; LABCYTE INC.; Leucine Rich Bio Pvt Ltd.; Microbiome Insights; MICROBIOME THERAPEUTICS, LLC; Thermo Fisher Scientific Inc.; Molzym GmbH & Co. KG; Norgen Biotek Corp.; Phase Genomics Inc.; QIAGEN; Resphera Biosciences, LLC; Shoreline Biome; StarSEQ GmbH; Viome, Inc.; Zymo Research among others.

Key Insights in the report:

Key Developments in the Market:

Access Complete Report @ https://www.databridgemarketresearch.com/reports/global-microbiome-sequencing-market

Market Drivers

Market Restraints

Segmentation: Global Microbiome Sequencing Market

By Sequencing Technology

By Component

By Targeted Disease

By Application

By Research Type

By End-User

By Laboratory Type

ByGeography

Inquiry For Customize Report With Discount at :https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-microbiome-sequencing-market

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like Asia, United States, and Europe.Contact:Data Bridge Market ResearchTel: +1-888-387-2818Email:[emailprotected]

Read more:
Global Microbiome Sequencing Market 2020 Business Outlook with Pandemic Scenario Analysis and Forecast 2026|Oxford Nanopore Technologies; BaseClear...

Read More...

Personalized Medicine Market Growth By Manufacturers, Countries, Types And Application, End Users And Forecast To 2026 – 3rd Watch News

Saturday, July 11th, 2020

New Jersey, United States,- Verified Market Research sheds light on the market scope, potential, and performance perspective of the Personalized Medicine Market by carrying out an extensive market analysis. Pivotal market aspects like market trends, the shift in customer preferences, fluctuating consumption, cost volatility, the product range available in the market, growth rate, drivers and constraints, financial standing, and challenges existing in the market are comprehensively evaluated to deduce their impact on the growth of the market in the coming years. The report also gives an industry-wide competitive analysis, highlighting the different market segments, individual market share of leading players, and the contemporary market scenario and the most vital elements to study while assessing the Personalized Medicine market.

The research study includes the latest updates about the COVID-19 impact on the Personalized Medicine sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Leading Personalized Medicine manufacturers/companies operating at both regional and global levels:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

Industrial Analysis:

The Personalized Medicine market report is extensively categorized into different product types and applications. The study has a separate section for explaining the cost of raw material and the revenue returns that are gained by the players of the market.

The segmentation included in the report is beneficial for readers to capitalize on the selection of appropriate segments for the Personalized Medicine sector and can help companies in deciphering the optimum business move to reach their desired business goals.

In Market Segmentation by Types of Personalized Medicine, the report covers-

Bytype1

In Market Segmentation by Applications of the Personalized Medicine, the report covers the following uses-

Byapplication1

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=7106&utm_source=3WN&utm_medium=002

The Personalized Medicine market report provides successfully marked contemplated policy changes, favorable circumstances, industry news, developments, and trends. This information can help readers fortify their market position. It packs various parts of information gathered from secondary sources, including press releases, web, magazines, and journals as numbers, tables, pie-charts, and graphs. The information is verified and validated through primary interviews and questionnaires. The data on growth and trends focuses on new technologies, market capacities, raw materials, CAPEX cycle, and the dynamic structure of the Personalized Medicine market.

This study analyzes the growth of Personalized Medicine based on the present, past and futuristic data and will render complete information about the Personalized Medicine industry to the market-leading industry players that will guide the direction of the Personalized Medicine market through the forecast period. All of these players are analyzed in detail so as to get details concerning their recent announcements and partnerships, product/services, and investment strategies, among others.

Sales Forecast:

The report contains historical revenue and volume that backing information about the market capacity, and it helps to evaluate conjecture numbers for key areas in the Personalized Medicine market. Additionally, it includes a share of each segment of the Personalized Medicine market, giving methodical information about types and applications of the market.

Reasons for Buying Personalized Medicine Market Report

This report gives a forward-looking prospect of various factors driving or restraining market growth.

It renders an in-depth analysis for changing competitive dynamics.

It presents a detailed analysis of changing competition dynamics and puts you ahead of competitors.

It gives a six-year forecast evaluated on the basis of how the market is predicted to grow.

It assists in making informed business decisions by performing a pin-point analysis of market segments and by having complete insights of the Personalized Medicine market.

This report helps the readers understand key product segments and their future.

Have Any Query? Ask Our Expert @ https://www.verifiedmarketresearch.com/product/global-personalized-medicine-market-size-and-forecast-to-2026/?utm_source=3WN&utm_medium=002

In the end, the Personalized Medicine market is analyzed for revenue, sales, price, and gross margin. These points are examined for companies, types, applications, and regions.

To summarize, the Personalized Medicine market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Read the original:
Personalized Medicine Market Growth By Manufacturers, Countries, Types And Application, End Users And Forecast To 2026 - 3rd Watch News

Read More...

Impact of COVID-19 on Personalized Medicines 2020 Industry Growth, Size, Trends, Share, Opportunities and Forecast to 2026 – Jewish Life News

Saturday, July 11th, 2020

It is our aim to provide our readers with report for Personalized Medicines Market, which examines the industry during the period 2020 2026. One goal is to present deeper insight into this line of business in this document. The first part of the report focuses on providing the industry definition for the product or service under focus in the Personalized Medicines Market report. Next, the document will study the factors responsible for hindering and enhancing growth in the industry. After covering various areas of interest in the industry, the report aims to provide how the Personalized Medicines Market will grow during the forecast period.

The major vendors covered:

3G Biotech, Quest Diagnostics, Laboratory Corporation of America, Abbott, Agendia NV, Asuragen Inc, Becton Dickinson, CardioDx Inc., Foundation Medicine, Qiagen, Siemens Healthcare, Amgen, Bristol-Myers Squibb, GE Healthcare, Pfizer, Sanofi, 23andMe, Illumina. and more

The final report will add the analysis of the Impact of Covid-19 on Personalized Medicines Market.

Request a free sample copy @ https://www.reportsandmarkets.com/sample-request/global-personalized-medicines-market-report-2020?utm_source=jewishlifenews&utm_medium=38

The Personalized Medicines Market report between the years 2020 2026 will highlight the current value of the industry. At the same time, there is also an estimate of how much this line of business will be worth at the end of the forecast period. As it is our goal to maintain high levels of accuracy at all times, we will take a look at the CAGR of the Personalized Medicines Market. We make sure that all the information available in this report has excellent levels of readability. One way we achieve this target is by Personalized Medicines Market segmentation. Going through the report for 2020 2026 will bring our readers up-to-date regarding this industry.

While examining the information from this document, one thing becomes clear, the elements which contribute to increase in demand for the product or service. At the same time, there will be a focus on what drives the popularity of these types of products or services. This report is for those who want to learn about Personalized Medicines Market, along with its forecast for 2020 2026. Information regarding market revenue, competitive partners, and key players will also be available.

Segmentation

As discussed earlier, there is segmentation in the Personalized Medicines Market report, to improve the accuracy and make it easier to collect data. The categories which are the dividing factors in the industry are distribution channels, application, and product or service type. With this level of segmentation, it becomes easier to analyze and understand the Personalized Medicines Market. At the same time, there is emphasis on which type of consumers become the customers in this industry. When it comes to distribution channels, the Personalized Medicines Market report looks at the different techniques of circulation of the product or service.

Regional Overview

In this part of the Personalized Medicines Market report, we will be taking a look at the geographical areas and the role they play in contributing to the growth of this line of business. The areas of interest in this document are as follows Middle East and Africa, South and North America, Europe, and Asia Pacific. From the Personalized Medicines Market report, it becomes clear which region is the largest contributor.

Latest Industry News

From this Personalized Medicines Market report, the reader will also get to learn about the latest developments in the industry. The reason is that these products or services have the potential to disrupt this line of business. If there is information about company acquisitions or mergers, this information will also be available in this portion of the Personalized Medicines Market report.

If you have any special requirements about this Personalized Medicines Market report, please let us know and we can provide custom report.

Inquire more about this report @ https://www.reportsandmarkets.com/enquiry/global-personalized-medicines-market-report-2020?utm_source=jewishlifenews&utm_medium=38

About Us

ReportsAndMarkets.com allocates the globally available market research and many company reports from reputed market research companies that are a pioneer in their respective domains. We are completely an autonomous group and serve our clients by offering the trustworthy available research stuff, as we know this is an essential aspect of Market Research.

Contact Us

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

See the rest here:
Impact of COVID-19 on Personalized Medicines 2020 Industry Growth, Size, Trends, Share, Opportunities and Forecast to 2026 - Jewish Life News

Read More...

COVID-19 Impact on Precision Medicine Industry 2020: Global Market Size, Emerging Trends, Business Growth, SWOT Analysis by Top Manufacturers, Demand…

Saturday, July 11th, 2020

TheGlobal Precision Medicine Marketis estimated to grow at a CAGR of XX% by 2025. This report features the market growth analysis and forecasting for the growth and revenue up to 2025 allied with the Precision Medicine market.

Get Sample Copy of this Report at https://www.orianresearch.com/request-sample/559884

The market size estimations have been provided in terms of value (USD million). The global Precision Medicine industry report also identifies major market players and provides analysis in terms of company overview, Financials, products & services, market trends, recent developments and growth strategies.

Precision Medicine Market2019 Industry Research Report provides important statistics, analytical and comparative data to give a complete understanding of the market Share, Size, Growth, Rising Trends and Cost Structure analysis.

This report offers in-depth information obtained through extensive primary and secondary research methods. The information has been further assessed using various effective analytical tools.

The report puts special emphasis on the most important details of the Global Precision Medicine Market Report 2019 market, filtered out with the help of industry-best analytical methods

Regionally, North America, Latin America, Europe, Asia Pacific, And The Middle East & Africa constitute the key market segments.

Top Key Players Analyzed in Global Precision Medicine Marketare

Complete report on Precision Medicine Industry spread across 122 pages, profiling 10 companies and supported with tables and figures. For more details Enquire @https://www.orianresearch.com/enquiry-before-buying/559884

Key Benefit Of This Report:

Target Audience:

Get Direct Copy of this Report @https://www.orianresearch.com/checkout/559884

Major Points Covered in Table of Contents:

7 Global Precision Medicine Market By Product Type

8 Global Precision Medicine Market By Applications

9 Global Precision Medicine Market By Region

Customization Service of the Report:

Orian Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities

About UsOrian Researchis one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Continue reading here:
COVID-19 Impact on Precision Medicine Industry 2020: Global Market Size, Emerging Trends, Business Growth, SWOT Analysis by Top Manufacturers, Demand...

Read More...

What Are Precision Medicine and Personalized Medicine?

Saturday, July 11th, 2020

January 11, 2018 -Since the beginning of recorded history, healthcare practitioners have striven to make their actions more effective for their patients by experimenting with different treatments, observing and sharing their results, and improving upon the efforts of previous generations.

Becoming more accurate, precise, proactive, and impactful for each individual that comes under their care has always been the goal of all clinicians, no matter how basic the tools at their disposal.

But now, modern physicians and scientists are now able to take this mission far, far beyond the reach of their ancestors with the help of electronic health records, genetic testing, big data analytics, and supercomputing all the ingredients required to engage in what is quickly becoming truly precise and personalized medicine.

Precision medicine, also commonly referred to as personalized medicine, is one of the most promising approaches to tackling diseases that have thus far eluded effective treatments or cures. Cancer, neurodegenerative diseases, and rare genetic conditions take an enormous toll on individuals, families and societies as a whole.

Approximately 1.7 million new cancer cases were diagnosed in the United States in 2017. Around 600,000 deaths were expected during that year, according to the American Cancer Society. The Agency for Healthcare Research and Quality adds that the direct economic impact of cancer is around $80 billion per year loss of productivity, wages, and caregiver needs sap billions more from the economy.

Many of these cancers are preventable through lifestyle changes, such as quitting tobacco, improving weight and diet, or reducing alcohol consumption, but many are also the result of predispositions to certain diseases inherited along ethnic, racial, or familial lines.

Neurological diseases, including Alzheimers disease, produce similarly dire impacts. Alzheimers is the 6th leading cause of death in the United States, and the Alzheimers Association predicts that 16 million individuals will be living with the disease by 2050.

Alzheimers and other forms of dementia cost the US approximately $259 billion in 2017. As the population ages and dementia cases increase in number, those costs will top $1.1 trillion by 2050.

The financial, clinical, and social imperatives for finding cures for these and other conditions have led to a surge in interest around precision medicine. With much more digital data at their disposal and the computing power to crunch the numbers, researchers are now eagerly uncovering new relationships between genes, drugs, and populations.

Fully unlocking the secrets of how an individuals genetics impacts his or her likelihood of developing or surviving a particular condition would produce a fundamental revolution in the way providers approach the practice of medicine, moving the profession an incalculable distance from the basic experimentation of its prehistorical origins.

According to the Precision Medicine Initiative, precision medicine is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person.

Physicians have, of course, tailored their recommendations to individual factors such as age and gender, patient preferences, mobility levels, community resources, preexisting conditions, and other mitigating circumstances for many, many years.

The difference between a traditional shrewd assessment of a complex situation and true precision medicine is the degree of reliance on data especially genomic data to make decisions about specific treatment paths that may be more or less effective for the individual at hand.

Genomic data is a relatively new addition to the physicians toolkit, and researchers have barely begun to scratch the surface of what revolutionary insights are likely hidden in the human genetic code.

Genetic testing is getting quicker and cheaper, offering researchers the opportunity to collect larger volumes of data from more diverse patient groups.

By combining this data with clinical, pharmaceutical, and socioeconomic information, and then applying analytics to these integrated datasets, researchers and providers can observe patterns in the effectiveness of particular treatments and identify the genetic variations that may be correlated with success or failure.

Clinical trials can then be used to test and validate these hypotheses. If the results meet rigorous scientific standards, they may support future best practices or clinical guidelines for the treatment of specific conditions integrated into advanced clinical decision support systems.

Many stakeholders are starting to prefer the term precision medicine instead of personalized medicine to describe the use of data and genomics to tailor treatments to specific groups.

The National Research Council (NRC) has expressed concern that personalized medicine may be misconstrued to mean that completely individualized treatments are available for every unique patient, which is not the case.

In its 2011 report Towards Precision Medicine, the NRC states:

Precision medicine refers to the tailoring of medical treatment to the individual characteristics of each patient. It does not literally mean the creation of drugs or medical devices that are unique to a patient, but rather the ability to classify individuals into subpopulations that differ in their susceptibility to a particular diseaseor in their response to a specific treatment. Although the term personalized medicine is also used to convey this meaning, that term is sometimes misinterpreted as implying that unique treatments can be designed for each individual. It should be emphasized that in precision medicine, the word precision is being used in a colloquial sense, to mean both accurate and precise.

Personalized medicine has been falling out of favor since 2015, when President Barack Obama introduced the national Precision Medicine Initiative in his State of the Union speech, explained Muin J. Khoury, Director, Office of Public Health Genomics, Centers for Disease Control and Prevention, in a 2016 blog post.

Source: CDC

Precision medicine has overtaken personalized medicine as the preferred search term online, and the number of academic journal articles using precision instead of personalized has exploded.

The difference in search popularity is even more marked at the beginning of 2018, with precision medicine firmly the favorite among Google users in the United States.

The growing popularity of precision medicine over personalized medicine may be a good thing, Khoury said, as targeted therapies become more deeply integrated into everyday clinical care, requiring patient education and tempered expectations.

Source: Xtelligent Media

To be sure, precision medicine and personalized medicine are highly related and genomics plays a big role in both, said Khoury. However, even highly personalized information may or may not lead to improved health outcomes. Moreover, precision medicine approaches may lead to non-personalized interventions that can be used population-wide.

Direct-to-consumer (DTC) genetic testing kits, such as those offered by 23andMe or AncestryDNA, are an example of the divide between personalization and precision, he continued.

These commercial products can deliver very personalized information, but may not be particularly precise or actionable when it comes to an individuals health status or chances of developing specific conditions.

In many ways, DTC genetic tests are the opposite of precision medicine, observed Khoury. In spite of their deceptive appeal, they deliver uncertain information and create patient expectations that may align poorly with evidence; clinical priorities; or, in some cases, the patients best interests.

Using precision medicine instead of personalized medicine as the latter continues to slide out of favor may help to ensure clarity for patients who are interested in learning more about tailored care.

Interest in Genetic Testing Brings Precision Medicine Challenges

Artificial Intelligence, Genomics Combo Boosts Precision Medicine

Many of the scientific terms used to describe the progress and challenges of precision medicine require highly specialized knowledge to fully understand, which can be an obstacle for providers who wish to educate patients about precision medicine, its opportunities, and its limitations.

While most people are familiar with the concept of DNA and its basic role in many diseases, painting a fuller picture of how and why targeted therapies work may involve providing explanations of several of the following terms.

Genomics

The genome is an organisms complete set of genetic material. DNA includes coding regions, or genes, that govern the function of proteins, as well as non-coding sequences that perform regulatory functions. Genomics is the study of these materials.

Genetics

A gene is a subset of the genome that codes for a molecule that has a specific function, such as governing a persons eye color, blood type, or predisposition for certain diseases. Genes can acquire mutations when passed along through families, resulting in inherited conditions. Variations in an individuals phenotype, or the sum of its observable physical or behavioral characteristics, are due part to how individual genes combine to produce those traits.

Researchers are still discovering incredibly complex relationships between genes and diseases. The rapid advance of genetic research in the early years of the 21st century has been supported by initiatives like the Human Genome Project, which produced a composite genetic sequence that is freely available to the public. Scientists can compare cancer cells, for example, with this data to understand where and how specific mutations occur and what their impacts might be.

Genetic sequencing

Genetic sequencing, or DNA sequencing, is the process of determining the order of the four chemical building blocks of DNA (adenine, guanine, cytosine, and thymine) for an individual organism. The order of these chemicals in each strand of DNA dictates the type of genetic information included in a segment of DNA.

Researchers can identify which sections of a DNA molecule contain genes and which include regulatory information, allowing them to pinpoint differences between individuals with certain traits and those without. The human genome contains around 3 billion pairs of the four chemical bases of DNA, which all together provide the instruction manual for a living organism.

Source: National Institutes of Health

Since its start in the early 1970s, genetic sequencing has become so quick and inexpensive that healthcare providers can routinely order genetic testing for patients suspected of having conditions with a genetic component.

The falling prices and rising speed of these tests has been a significant catalyst for precision medicine. Interest in genetic testing has skyrocketed in recent years, with 90 percent of patients in one recent survey expressing some level of curiosity about receiving a genetic test.

Next-generation sequencing

Next-generation (next-gen) sequencing is a collection of techniques that have further enhanced the speed and detail of genetic sequencing.

Instead of sequencing an individuals entire genetic code from scratch every time, next-gen techniques sequence fragments of an individuals DNA, called reads, and then use algorithms to compare the results to a DNA library to fill in the gaps. Any differences or mutations can be identified during the process.

Next-gen sequencing allows laboratories to complete the process more quickly, helping to meet the growing demand for their services. The techniques are being developed and refined very rapidly as life science companies rush to provide researchers and healthcare organizations with one of the essential tools for precision care.

CRISPR

CRISPRs (Clustered Regularly Interspaced Short Palindromic Repeats), are part of an organisms bacterial defense system, first discovered by Francisco Mojica, a scientist at the University of Alicante in Spain.

They consist of repeating sequences of genetic code, interrupted by spacer sequences remnants of genetic code from past invaders. The system serves as a genetic memory that helps the cell detect and destroy invaders (called bacteriophage) when they return, says the Broad Institute.

CRISPRs form the basis for CRISPR-Cas9, a gene editing technology that allows researchers to target specific stretches of genetic code and alter the DNA within them.

This futuristic capability may allow scientists to correct damaging mutations or susceptibilities to diseases in living organisms without side effects from traditional pharmaceutical therapies and even rectify genetic conditions for which no pharmaceutical option exists.

Pharmacogenetics

Pharmacogenetics is the study of how genetic differences influence the metabolic pathways of drugs, or how individuals respond to specific pharmaceutical interventions based on their unique genetic makeup. This science forms the basis of many precision medicine efforts, such as choosing individualized drug combinations to attack a specific type of cancer.

For example, the drug Tamoxifen is widely used to treat breast cancer or prevent a recurrence, but up to 10 percent of individuals have a version of a gene that results in resistance to its positive effects.

Before prescribing the drug, providers can order a genetic test to see whether the individual has a genetic makeup that would reduce the effectiveness of the drug.

Pharmacogenetics (often used interchangeably with pharmacogenomics) is also important for drug safety research and identifying potential negative drug-drug or drug-gene interactions.

Biomarkers

Biomarkers are widely used across all forms of clinical practice to indicate that a disease, infection, toxicity, or other process is taking place within an organism.

Biomarkers may include lead levels in the blood, antibodies after an infection, thyroid hormone levels, or prostate specific antigen (PSA), as well as molecular signatures can indicate whether a patient is likely to respond to certain advanced therapies.

The exploration of biomarkers for identifying and treating cancer and similar conditions with genetic components is one of the main branches of precision medicine research.

Biobanking

In many respects, genomic research is at its most useful when conducted at scale. In order to identify patterns in populations in a reliable and repeatable manner, researchers must have access to large volumes of patient data.

In addition, researchers investigating rare genetic conditions or those targeting therapies to very specific populations will only be able to find suitable candidates for clinical trials if they have as many individuals as possible to choose from.

Biobanking, or the act of collecting and storing samples of DNA from groups of individuals (typically blood, saliva, and/or urine), allows researchers to access larger pools of potential subjects who have already signaled a willingness to participate in studies or trials.

Biobanks have proliferated in recent years as healthcare provider systems and government agencies recognize the need to have as much data available for research as possible.

Large health systems such as Geisinger Health System, Northwell Health, and Kaiser Permanente have established their own biobanks to support their research communities, while the Department of Veterans Affairs currently oversees one of the largest biobanks in the country.

The All of Us research initiative, discussed further below, has also launched multiple efforts to kick off its enrollment processes with a special emphasis on collecting data from traditionally underserved communities and ethnically diverse participants.

70% of Orgs Planning Precision Medicine Will Deploy Within 2 Years

Pharma, Tec Companies Set to Restructure Healthcare Big Data Market

2015 was a pivotal year for precision medicine as former President Obama launched the Precision Medicine Initiative (PMI) during that years State of the Union address.

The project, which received bipartisan support at the time, was designed to jumpstart research across the public and private sectors while encouraging everyday patients and their families to get involved in sharing their data and participating in clinical trials.

Iwant the country that eliminated polio and mapped the human genome to lead a new era of medicine one that delivers the right treatment at the right time, Obama said at the time. In some patients with cystic fibrosis, this approach has reversed a disease once thought unstoppable.

Tonight, Im launching a new Precision Medicine Initiative to bring us closer to curing diseases like cancer and diabetes and to give all of us access to the personalized information we need to keep ourselves and our families healthier.

The centerpiece of the initiative was the PMI Cohort, now called the All of Us Research Program. With the goal of recruiting one million Americans to participate, All of Us will eventually provide researchers with access to huge volumes of data to fuel their work.

Researchers will use data from the program to learn more about how individual differences in lifestyle, environment and biological make-up can influence health and disease,said the National Institutes of Health (NIH) in 2017.

By taking part, people will be able to learn more about their own health and contribute to an effort that will advance the health of generations to come.

Socioeconomic, racial, and ethnic diversity are high priorities for the program, which has started to recruit community organizations to spread the word among their participants.

Community partners are integral toAll of Us, said Eric Dishman, Director of the All of Us program. This first-of-its-kind program seeks to include people from all walks of life, and these community partner awardees were selected to help achieve that goal.

The NIH is primarily responsible for overseeing the All of Us project, but is working with conjunction with the FDA, HHS, the Department of Veterans Affairs, Department of Defense, the National Cancer Institute (NCI) within the NIH, and a number of healthcare industry stakeholders to facilitate the Precision Medicine Initiative as a whole.

On a similar theme as the PMI, former Vice President Joe Biden oversaw the launch of the national Cancer Moonshot, supported by funds from the landmark 21st Century Cures Act passed in late 2016.

The Cancer Moonshot aims to use the growing wealth of available healthcare big data to foster breakthroughs in research and cancer treatment. The collaborative effort is bringing together both public and private organizations to support research and develop new treatments for deadly diseases.

Everywhere I travelled [meeting with researchers and patients], I was told that data are key, and we have an unprecedented amount and diversity of data being generated daily through genomics, family history records, lifestyle measurements, and treatment outcomes, said Biden in a 2016 report on the future direction and challenges of the initiative.

We now have the capability to realize the promise of all of these data because of advances in super computing power. Researchers can analyze enormously complex and large amounts of data to find answers we couldnt just five years ago.

CMS may be planning to add even more data to the pool by considering coverage options for a new FDA-approved genetic test that can identify key biomarkers for multiple cancers.

The FoundationONe CDx diagnostic test can flag mutations in 324 genes and two genomic signatures in solid tumors.

The test can also suggest which of 15 existing FDA-approved cancer treatments would be most applicable to patients with one of five tumor types, including non-small cell lung cancer, melanoma, breast cancer, colorectal cancer, and ovarian cancer.

Expanding the availability of such a test to Medicare beneficiaries could rapidly accelerate the goals of both the Cancer Moonshot and the larger Precision Medicine Initiative.

Source: White House Archives

Top 5 Basics to Know about the Precision Medicine Initiative

Mayo Gets $142M to Create Precision Medicine Initiative Biobank

Federal investment is only the beginning of the healthcare systems involvement in furthering precision medicine. The private sector is rapidly embracing similar goals, which align well with existing value-based reimbursement and population health management initiatives.

Academia has been particularly active in the precision medicine ecosystem, combining computer science and engineering breakthroughs with laboratory work and clinical discovery. Similarly, pharmaceutical companies angling to expand their drug portfolios are heavily investing in research and collaborations with healthcare providers and others.

Even Silicon Valley figures like Bill Gates and Mark Zuckerberg are addressing the urgent need for precision medicine development: Gatesrecently announceda $50 million investment in data-driven Alzheimers research, while Zuckerberg and his wife, Dr. Priscilla Chan, madea $10 million donationto the UCSF Institute for Computational Health Sciencesto explore how to best reuse available datasets to produce new insights.

Many activities revolve around collaborations and partnerships between likeminded organizations looking to pool their computing power and share insights across research networks. Some notable examples include:

Geisinger Health Systemhas launchedits own National Precision Health Initiative which will leverage the data from 160,000 volunteer patients held in its MyCode Community Health Initiative biobank. The initiative will focus on developing strategic partnerships and new ventures while harnessing the existing resources within the Geisinger network.

Link:
What Are Precision Medicine and Personalized Medicine?

Read More...

Personalized Medicine Market is Anticipated to Attain a Market Value of US$XX by the End of 2016 2026 – Cole of Duty

Saturday, July 11th, 2020

Global Personalized Medicine market size will reach xx million US$ by 2025, from xx million US$ in 2018, at a CAGR of xx% during the forecast period. In this study, 2018 has been considered as the base year and 2019-2025 as the forecast period to estimate the market size for Personalized Medicine .

This industry study presents the global Personalized Medicine market size, historical breakdown data (2014-2019) and forecast (2019-2025). The Private Plane production, revenue and market share by manufacturers, key regions and type; The consumption of Personalized Medicine market in volume terms are also provided for major countries (or regions), and for each application and product at the global level.

Request Sample Report @ https://www.futuremarketinsights.co/reports/sample/REP-GB-1511

Global Personalized Medicine market report coverage:

The Personalized Medicine market report covers extensive analysis of the market scope, structure, potential, fluctuations, and financial impacts. The report also enfolds the precise evaluation of market size, share, product & sales volume, revenue, and growth rate. It also includes authentic and trustworthy estimations considering these terms.

The Personalized Medicine market has been reporting substantial growth rates with considerable CAGR for the last couple of decades. According to the report, the market is expected to grow more vigorously during the forecast period and it can also influence the global economic structure with a higher revenue share. The market also holds the potential to impact its peers and parent market as the growth rate of the market is being accelerated by increasing disposable incomes, growing product demand, changing consumption technologies, innovative products, and raw material affluence.

The following manufacturers are covered in this Personalized Medicine market report:

Key Players

Some key players in this market are Roche Holding AG, Astra Zeneca PLC, Vertex Pharmaceuticals Inc., Qiagen Inc., BD (Becton Dickinson & Co., Merck & Co. Inc., Pfizer Inc., American Association for Cancer Research, Siemens Healthcare Diagnostics, Inc. among others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

The report covers exhaustive analysis on:

Regional analysis includes

North America (U.S., Canada)

Latin America (Mexico. Brazil)

Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)

Eastern Europe (Poland, Russia)

APEJ (China, India, ASEAN, Australia & New Zealand)

Japan

Middle East and Africa (GCC, S. Africa, N. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Detailed overview of parent market

Changing market dynamics in the industry

In-depth market segmentation

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape

Strategies of key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint.

NOTE All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Request Methodology On This Report @ https://www.futuremarketinsights.co/askus/REP-GB-1511

The study objectives are Personalized Medicine Market Report:

We offer tailor-made solutions to fit your requirements, request[emailprotected] https://www.futuremarketinsights.co/customization-available/REP-GB-1511

This report includes the estimation of market size for value (million USD) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Personalized Medicine market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Continue reading here:
Personalized Medicine Market is Anticipated to Attain a Market Value of US$XX by the End of 2016 2026 - Cole of Duty

Read More...

Real-world data coming into its own despite bad reputation in times gone by – BioWorld Online

Saturday, July 11th, 2020

The use of real-world data (RWD) and real-world evidence (RWE) in regulatory decision-making may seem more aspirational than practical at times, but that state of affairs is changing rapidly. Wendy Rubenstein, director of personalized medicine at the U.S. FDAs Center for Devices and Radiological Health, said contemporary versions of these real-world sources of evidence are of progressively higher quality in recent years, and thus RWE and RWD may soon hit their strides as mature sources of data with which regulators are increasingly comfortable.

Rubenstein was speaking on a recent webinar hosted by the Medical Device Innovation Consortium, the public-private partnership between the FDA and device makers with the objective of modernizing regulatory science. The theme of the webinar was a framework developed by MDIC for the use of RWE and RWD for in vitro diagnostics, and Rubenstein said that for perhaps the majority of randomized, controlled trials, the benefit is generally diluted when that therapy or diagnostic is rolled out for routine clinical use. The external validity of the results of studies is not always sufficiently vigorous to withstand translation into general clinical use, particularly when the enrolled study population fails to reflect the population(s) that will use or receive the device, she said.

Collection of RWD in the premarket phase should help mitigate these problems and more accurately predict similar results in real-world settings, Rubenstein said, adding that RWDs reputation has not always been the best and has maybe got a bit of a bad rap as a consequence. Recently, however, the increasing quality of RWE and RWD is changing minds, and Rubenstein said the process involved in developing the MDIC framework is helping us get to that higher level.

Pandemic has quickened stakeholder interest

The FDA has given the nod to more than 100 diagnostic emergency use authorizations (EUAs) in connection with the COVID-19 pandemic, and Rubenstein said the pandemic has had the effect of unifying the purpose of regulators and test developers alike. COVID-19 can actually result in driving the community toward a common purpose of generating evidence on real test performance for molecular diagnostics for the SARS-CoV-2 virus, she said, but this will require a definition of common data elements to support use purposes. Still, Rubenstein advised that the pandemic is likely to come to an end before stakeholders can stand up a fully developed infrastructure needed to make routine use of RWD.

In other words, theres an opportunity to use the activation energy created by the pandemic to build an infrastructure that will extend beyond COVID, Rubenstein said. However, all of this will require the use of the Standardization of Lab Data to Enhance Patient-Centered Outcomes and Value-Based Care (Shield) project. Shield is another public-private partnership, and is focused on data lab standards, and is one of the pillars needed to make the data accessible. The development of mapping manuals for logical observation identifier names and codes (LOINCs) will also prove crucial because of a considerable amount of ambiguity with regard to LOINCs, which has up to now has made it difficult to aggregate data about a tests routine clinical use, sometimes even within a health care organization.

Danelle Miller, director of global regulatory policy at Indianapolis-based Roche Diagnostics Corp., and chair of the RWE working group (WG) at MDIC, made reference to the August 2017 FDA guidance for the use of RWE to support regulatory decision-making. Miller said industry welcomed the FDA guidance enthusiastically, largely because the guidance goes a long way toward clarifying when RWE can be leveraged for regulatory decision-making. She said the MDIC framework represents years of hard work and robust discussions among the parties, including industry, the FDA and the Centers for Disease Control and Prevention. The comment period for the MDIC framework closes June 15.

The scope of the framework is largely limited to the current landscape for RWE and real-world data (RWD) and, in the case of the latter, how it can be used for both premarket regulatory decision-making and for postmarket issues. The framework also proposes and approach for evaluating the relevance and reliability of RWD to assess data quality for regulatory decisions, and proposes a few study designs and methods for generating valid scientific evidence.

The task for the work groups included development of a glossary for RWE and RWD, as well as a survey to determine how IVD manufacturers are currently using RWE throughout product life cycles. The WG undertook a literature search for use of RWE and RWD, but there was a considerable amount of effort put into a description of the requirements for data quality and the methods for using RWD.

Alternative study designs available

One of the complicating factors in leveraging real-world sources of evidence for diagnostics in the premarket phase is that diagnostic studies dont often strongly resemble the types of trials employed for therapeutic devices. One approach to overcoming this limitation is the use of a virtual clinical performance study, which can be used to support premarket approval or clearance of an IVD. The MDIC paper spells out several other approaches as well, but among the regulatory considerations for any of these studies is whether the data are fit for the purpose at hand.

The assessment to determine whether those data are fit for purpose includes a determination of whether the data are both accurate and complete, and whether those data meet key reliability and relevance criteria to support the sought-after regulatory decision. Test developers should also ensure they are using data standards the FDA will accept, and may want to engage with the agency via the Q-submission process to clear out any potential issues before the developer invests more than a modest amount of resources toward the application.

Visit link:
Real-world data coming into its own despite bad reputation in times gone by - BioWorld Online

Read More...

Drug Discovery Informatics Market Size Estimation, Future Insights, Growth Dynamics, COVID-19 Impact and Applications By 2023 – Cole of Duty

Saturday, July 11th, 2020

Drug Discovery Informatics MarketScope

The GlobalDrug Discovery Informatics Marketstood at USD 1,680.6 million in 2017. It is expected to enjoy a high valuation at a 11.5% CAGR from 2018 to 2023 (forecast period). Factors driving market growth include impending need to curtail drug discovery and development costs, focus on drug discovery, increasing expenditure on R&D, and large prevalence of chronic diseases. According to the WHO report of 2001, chronic diseases accounted for 60% of the deaths that year. Nearly 46.4% of the deaths in 2020 will be credited to chronic diseases triggering the market demand. But setup of laboratories and high costs of informatics software can restrict the market growth.

Drug discovery plays a vital role in the life sciences, pharmaceutical, and biopharmaceutical industries. The amount of data accumulated from clinical trials and tests is vast and requires software to sift through. New approaches in drug discovery informatics for accumulating and processing information can lead to faster commoditization of drugs, medicines, and vaccines. The global drug discovery informatics market report by Market Research Future (MRFR) contains a comprehensive overview followed by pertinent factors and drawbacks for the period between 2018 and 2023.

Request Free Sample Copy at:https://www.marketresearchfuture.com/sample_request/7831

Drug Discovery Informatics MarketSegmentation

The global drug discovery informatics market is segmented by product, mode, service, and end-user.

By product, drug discovery informatics market is segmented into discovery informatics and development informatics.

By mode, drug discovery informatics market is is divided into in-house informatics and outsourced informatics.

By service, drug discovery informatics market is is segmented into clinical trial data management, sequencing and target data analysis, molecular modeling, docking, and others. The sequencing and target data analysis segment is touted to dominate the market during the forecast period due to increasing applications in targeted analysis. Inclination towards personalized medicine is bound to drive the segment demand and contribute to the global drug discovery informatics market growth.

By end-user, drug discovery informatics market is is segmented into contract research organizations, pharmaceutical & biotechnology industries, and others.

Drug Discovery Informatics Market Regional Analysis

Europe, Asia Pacific (APAC), the Americas, and the Middle East & Africa (MEA) are regions covered in the global drug discovery informatics market report.

The Americas dominated the global market in 2017 due to presence of prominent names such as International Business Machines, PerkinElmer Inc., and ThermoFisher Scientific Inc. Establishment of next-generation sequencing and chemical laboratories in the U.S. and Canada, boom in pharmaceutical and biopharmaceutical industries, and sophisticated healthcare infrastructure.

Europe is the second largest region and highly lucrative for the global drug discovery informatics market till 2023. This can be credited to funding allocated to research and development on drug research by governments, growth in therapeutic discovery centers, and successful activities by research and academic institutes, universities, and other prestigious centers.

APAC can be ensured to display a profitable growth rate during the forecast period due to the large geriatric population and heavy prevalence of chronic diseases. Awareness of the software, adoption of the software in pharma and biopharma companies, and a rise in clinical studies can drive the regional market growth. Lower costs, lax policies and regulations, and a spurt in clinical trials are other factors making the region lucrative for the global drug discovery informatics market.

Drug Discovery Informatics Market Competitive Outlook

Certara, L.P., Charles River Laboratories, Inc., Jubilant Life Sciences Ltd., Novo Informatics Pvt. Ltd., Dassault Systmes, IO Informatics, Inc., Thermo Fisher Scientific, Inc., Infosys Limited, Selvita, International Business Machines Corporation, PerkinElmer, Inc., Collaborative Drug Discovery Inc., and GVK Biosciences Private Limited are prominent players of the global drug discovery informatics market.

Drug Discovery Informatics Industry News

Schrdinger, a U.S. based drug discovery company, recently received nearly USD 232 million in funding in January 2020. The platform developed by the company can assess the chemical composition of molecules and predict the properties during mixing and expedite the process rapidly saving production costs in the process.

Browse More Details at:https://www.marketresearchfuture.com/reports/drug-discovery-informatics-market-7831

NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: [emailprotected]

Read the rest here:
Drug Discovery Informatics Market Size Estimation, Future Insights, Growth Dynamics, COVID-19 Impact and Applications By 2023 - Cole of Duty

Read More...

What’s working in the APAC countries’ fight against cancer? – World Economic Forum

Saturday, July 11th, 2020

The battle against COVID-19 is dominating our attention right now and rightly so. The pandemic is impacting economies, societies and individuals across all sectors, but especially in healthcare. However, while we focus on tackling the pandemic, it is critical that we dont lose sight of our efforts to address the devastating impact of other diseases, such as cancer.

With healthcare systems focused on the fight against COVID-19, we are witnessing disruption across the spectrum of cancer care and delivery. There are multiple contributing factors, ranging from closures of screening programmes to public transport lockdowns hindering access to health facilities, delays to important consultations leading to disease progression and high rates of sickness among health workers dramatically reducing the numbers of available staff. Cancer patients are also more vulnerable to becoming severely ill or dying from COVID-19 and many, understandably, fear coming into hospitals or clinics during this time.

Nowhere is the battle against cancer fought more bitterly than in Asia Pacific (APAC). Almost half of the worlds cancer cases are found here, and by 2030 the number of people battling cancer is expected to surge by around 35%, with mortality rising by almost 40%. COVID-19 has emphasised the importance of making health systems robust and sustainable in the long-term, so that the impact of care delivery for non-communicable diseases like cancer is minimized during this and future outbreaks.

When addressing significant public health issues like COVID-19, cardiovascular disease or cancer can sometimes feel like an insurmountable challenge for countries faced with limited resources and competing priorities.

A new report from the Economist Intelligence Unit (EIU), supported by Roche, analyses the readiness of 10 APAC countries to address the cancer challenge. The report highlights existing gaps and progress made with recommendations on how to boost this progress towards more sustainable and equitable cancer care. Advances in cancer planning and preparedness vary across countries, but the improvements highlighted span several areas from research and policy development to the expansion of national cancer registries and implementation of universal health coverage (UHC) programmes.

Australia ranks highest of all countries evaluated for overall cancer preparedness, followed by Malaysia, South Korea, China and Thailand. This success is due in part to these countries demonstrating strong examples of cancer registries, which play a vital role in generating meaningful, evidence-based, long-term planning for cancer. The Philippines stands out as one of the only lower-middle-income countries evaluated with a comprehensive cancer plan.

Cancer preparedness in APAC

Image: Economist Intelligence Unit, Roche

We also see a strong link between a countrys cancer readiness and its overall healthcare spending. Indonesia and Malaysia showed strong commitment in this area; they registered the strongest growth in healthcare spending of all the countries evaluated, with average annual increases of 5.7% and 3.2% respectively. The WHO notes higher government spending on health is also associated with lowering income inequality, in particular for fast-growing countries.

Spending more on health is a way to reduce inequality

Image: WHO Health Expenditure Report 2019

UHC generates benefits to societies far beyond the health sector, strengthens health systems governance and improves overall population health outcomes. Across Asia, positive steps have been taken towards universal access to cancer care. Thailand demonstrates strong implementation of UHC programmes alongside higher-income countries like Australia, South Korea and Japan. Thailand is also the only country evaluated in which all cancer medicines were found to be fully accessible and reimbursable via their public health system, an impressive achievement unmatched even in highly developed nations. This increased focus on UHC programmes is in line with the recent WHO report that recommends the inclusion of prevention, early diagnosis, screening and appropriate treatment of non-communicable diseases in essential personalised healthcare services and UHC benefit packages.

Theres no getting away from the fact that the COVID-19 crisis has magnified healthcare challenges for populations and, in turn, policy and decision-makers. So how do we double down on this progress in a post-COVID-19 world to ensure we continue along a faster, upwards trajectory?

Gaps in service availability experienced by middle-income countries like China, Malaysia, Indonesia and the Philippines, including the under-provision of equipment, oncology specialists and infrastructure, are a major area of opportunity. If COVID-19 has shown us anything, it is that digital technology can play a critical role in addressing these gaps. The pandemic has forced healthcare systems to adopt new ways of working, to ensure cancer patients continue to receive essential care. Places like Thailand and Hong Kong are reaching more patients in need through the launch of virtual clinics and teleconsultations for remote areas. Australia and China are harnessing artificial intelligence to aid faster, more accurate diagnosis.

There is also a clear need to establish strong, cross-sector partnerships to collaborate on research and invest in areas like big data analytics and personalised medicine to significantly improve patient outcomes.

In Taiwan, for instance, Roche is partnering with the government to foster personalized healthcare with a focus on tailoring cancer treatment to individual patients for the best outcomes. The objective is to provide targeted treatment through precise genomic analysis and to reduce unnecessary medical expenses while improving the quality of healthcare.

Each year, $3.2 trillion is spent on global healthcare making little or no impact on good health outcomes.

To address this issue, the World Economic Forum created the Global Coalition for Value in Healthcare to accelerate value-based health systems transformation.

This council partners with governments, leading companies, academia, and experts from around the world to co-design and pilot innovative new approaches to person-centered healthcare.

While progress is undoubtedly being made in tackling the cancer challenge across APAC, there is still a long way to go. Excess cancer mortality remains a serious concern for lower-and middle-income countries. Cancer not only takes lives but also can result in severe economic hardship.

As someone who has spent a significant amount of time in healthcare and seen first-hand the devastating impact of the pandemic on cancer patients, I believe that a data-driven future holds the most potential to build resilient health systems for the future. Better data can help us work smarter and faster to respond to issues like COVID-19 and future health challenges. Digital and personalised healthcare can play an important role in advancing UHC, making health systems more sustainable, efficient and accessible and allowing policy-makers to better optimise resources.

Reducing the cancer burden requires an integrated, cross-sector, global response. This means creating systemic change in our healthcare ecosystems, and reorienting our relationships with the government, the outside world, and even with each other. While testing the limits of our health systems, COVID-19 has also highlighted the incredible achievements possible when we all band together.

See more here:
What's working in the APAC countries' fight against cancer? - World Economic Forum

Read More...

Demand for Anti Cd2-0 Monoclonal Antibodies Market to Witness Rapid Surge During the Period 2017 2025 – Cole of Duty

Saturday, July 11th, 2020

Anti-CD20 monoclonal antibodies are widely used in the treatment of B-cell malignancies. Anti-CD20 monoclonal antibodies are advantageous as they have enhanced killing activities and improves CD20 levels on the cell surface to increase the activity of lymphoma therapy. Since the inception of monoclonal antibodies, various type of potential mechanisms has been developed to increase the therapeutic efficiency of anti-CD20 monoclonal antibodies. This laid emphasis on developing next generation of anti-CD20 monoclonal antibodies to supplement additional potency in terms of functionality and efficacy. Anti-CD20 monoclonal antibodies work by targeting expressed CD20 marker on mature B cells and malignant B cells. This cascade of series works by complementing with the marker to deliver immunological attack from complement and FcR-expressing innate effectors (macrophages). This result in producing transmembrane signals by CD20 on engagement with anti-CD20 monoclonal antibodies, this favorable mechanism is utilized in malignant disease and autoimmune disorder treatment. Potential benefits from anti-CD20 monoclonal antibodies laid emphasis on developing next-generation anti-CD20 monoclonal antibodies and are currently in clinical trials.

To remain ahead of your competitors, request for a sample [emailprotected]https://www.persistencemarketresearch.com/samples/20833

The market for anti-CD20 monoclonal antibodies is primarily driven by increasing research and development activities in generating potent anti-CD20 monoclonal antibodies. Various research funding and grants, and investment are done by both private and government bodies to support R&D activities and are driving the growth of anti-CD20 monoclonal antibodies market. In addition, rising demand for personalized medicine coupled with increasing use of immunotherapy, and potential benefits from the treatment in terms of fewer side effects, low cost of production are also impelling the market growth of anti-CD20 monoclonal antibodies. However, the high cost of production, the presence of alternative therapies such as chemotherapy and drugs, and stringent rules and regulations are the major obstacles to the growth of anti-CD20 monoclonal antibodies market.

To receive Methodology request here@ https://www.persistencemarketresearch.com/methodology/20833

The global anti-CD20 monoclonal antibodies market can be segmented on the basis of product type, end-user, and region.

The introduction of monoclonal antibodies has revolutionized targeted therapy for cancer. Since its introduction, various technological advancement has been made in generating a novel products such as next generation anti-CD20 monoclonal antibodies are humanized monoclonal antibodies, whereas first generation anti-CD20 monoclonal antibodies are chimeric monoclonal antibodies. In addition, some of the anti-CD20 monoclonal antibodies are enhanced to improve effector functions, including improvement in FcR binding sites. The emergence of logistic services and e-commerce websites are also a vital component in boosting the growth of anti-CD20 monoclonal antibodies market.

To receive extensive list of important regions, Request TOC here @ https://www.persistencemarketresearch.com/methodology/20833

Geographically, global anti-CD20 monoclonal antibodies market can be segmented into North America, Latin America, Europe, Asia-Pacific and Middle East & Africa. The market in North America is anticipated to show the largest market share for anti-CD20 monoclonal antibodies, followed by Europe, owing to the presence of sophisticated healthcare infrastructure. In addition, proper reimbursement of therapy procedure, and increasing awareness about personalized medicine among the general population are also gardening the market growth of anti-CD20 monoclonal antibodies. The market in Asia-Pacific region is estimated to grow at fastest CAGR over the forecast period owing to the presence of large population base, and increasing research and development activities supported by private and public bodies. However, the market in the Middle East & Africa shows the steady growth during the forecast period.

Some of the market participants in the global anti-CD20 monoclonal antibodies market are

Read the original here:
Demand for Anti Cd2-0 Monoclonal Antibodies Market to Witness Rapid Surge During the Period 2017 2025 - Cole of Duty

Read More...

[Webinar] The Dos and Donts of Power of Attorneys and Living Wills – July 22nd, 12:00 pm – 1:00 pm ET – JD Supra

Friday, July 10th, 2020

July 22nd, 2020

12:00 PM - 1:00 PM ET

Whether you have been named power of attorney or have named someone to act as yours, it is crucial to understand the legal obligations and restrictions of power of attorney and living wills.

In this webinar, Whitney OReilly will provide tips and tricks for getting the most out of your power of attorney or living will, from making sure the appropriate parties are informed of their role to establishing a way of communicating the directives to hospitals, living facilities, and financial managers. She will highlight some of the key questions individuals should ask in the process of determining their power of attorney and creating living wills and will review the impact recent legislation has had on the power of attorney and living wills.

This webinar will feature a brief Q&A with Michael Snyder, who recently worked with the firm to manage the legal ramifications of sickness and death. Michael is the chair of the Department of Genetics and the director of the Center for Genomics and Personalized Medicine at Stanford University School of Medicine.

Read more:
[Webinar] The Dos and Donts of Power of Attorneys and Living Wills - July 22nd, 12:00 pm - 1:00 pm ET - JD Supra

Read More...

NantHealth Points To The Future Of Healthcare – Seeking Alpha

Friday, July 10th, 2020

MantHealth (NH) offers cancer molecular profiling solutions that enable personalization in a number of cancer treatments. This business, which has been lingering for a couple of years has received an important FDA approval which makes approval for Medicare and Medicaid use very likely. This, together with the sale of their Connected Care business has boosted the stock price significantly, but we think it's not too late to step on board.

The company is also is enabling a more integrated and data-driven healthcare solution through its two SaaS platforms, which are growing and account for most of the company's revenues to date.

These proven integration solutions are offered to an industry, which as they claim (and, dare we say, not without reason) suffers from a host of unnecessary complexity and inefficiencies, most notably:

Because of these inhibitions, the healthcare system is struggling to make the shift towards a more holistic, data-driven approach, the culmination of which is individualized medicine.

Personalized medicine is based on personalized data that is increasingly becoming available through advances in molecular medicine and real-time biometrics (remote monitoring devices and the like).

These solutions, like the company's own GPS business, generate a veritable deluge of data which, for a coordinated and individualized approach need to be collected, analyzed and distributed, and it's here where the company's SaaS solutions intervene and add value. We'll quickly introduce the company's solutions below.

From the 10-K:

GPS Cancer is a comprehensive molecular profile that integrates whole genome/exome (DNA) sequencing of tumor and normal germline samples and whole transcriptome (RNA) sequencing, providing oncologists with insights into the unique molecular signature of a patients cancer to inform personalized treatment strategies.

What GPS Cancer does is comparing the patient's whole genome/exome sequencing of a persons tumor sample with their normal sample in order to highlight molecular alterations that are specific to their tumor DNA.

These alterations are then subsequently confirmed by RNA sequencing. All this enables the matching of these alterations with drugs that might be effective against tumors containing the specific change. And these solutions are constantly fine-tuned by machine learning.

This is the company's blood based test that allows non-invasive profiling of tumors and monitoring quantitative response to treatment, from the 10-K:

Liquid GPS looks beyond cfDNA to cfRNA, which allows profiling and trending of actionable biomarkers that cannot be assessed through cfDNA alone. In addition to providing molecular insight into key guidelines-based biomarkers (e.g., EGFR, ALK, ROS1, KRAS), this powerful RNA-based approach enables a variety of capabilities and applications not typically available from a liquid biopsy test.

It is able to monitor targeted therapies, immunotherapy and chemotherapy responses.

This is the company's SaaS based decision support system which provides evidence-based clinical decision support for physicians who are threatened to be overwhelmed by today's rapid advancements in molecular and biometric medicine.

Eviti centralizes stuff like clinical content, treatment cost from Medicare reimbursements and treatment toxicity data. It has access to over 7600 clinical trials and 4000+ evidence-based treatment regimes.

NaviNet Open is a payer-provider workflow collaboration platform in order to increase efficiency, lower cost, improve provider satisfaction and enable communication between health plans and providers.

The company sold its Connected Care business for $47M in February to Masimo (MASI), exiting DCX, VCX, HBox and Shuttle Cable. The Connected Care business generated $1.2M in sales in Q1, a small part of overall revenue ($23M).

While operational performance has improved, the company hasn't been able to grow much in the past four years:

Data by YCharts

After the sale of its Connected Care business, the company has two revenue categories:

To date, the company's SaaS revenue generates most of its revenue but it does gain some revenue from sequencing and molecular analysis. However, last quarter saw a big decline to just $59K (down from $814K a year ago).

The stagnant revenue in part is just appearance as the company's SaaS business has been growing, from $60.7M in 2017 to $65.6M in 2018 to $72.8M in 2019, because the company de-emphasized its GPS business as costs were outweighing revenues. The company keeps on adding new customers (like here and here) to its SaaS businesses, a few were mentioned on the Q1CC.

The company keeps improving their products and adding new Eviti and NaviNet features.

For this business to take off, the wait is basically for a positive coverage determination from CMS, from the Q1CC:

we expect to continue to see minimal sequencing and molecular analysis revenue impact until we receive a positive coverage determination from CMS.

However, that event seems near, from the 10-K (our emphasis):

In the fourth quarter of 2019, we received FDA 510(K) authorization for Omics Core, the nations first FDA authorized whole exome tumor-normal in vitro diagnostic (IVD) that measures overall tumor mutational burden (TMB) in cancer tissue, completing a key step towards achieving Medicare coverage.

Which, together with the sale of the Connected Care business, explains the rally in the shares, from FinViz:

It's GPS business generated $2.55M in revenues in 2017, $3.13M in 2018 and $1.73M in 2019. Here too, apart from the FDA approval for Omics Core, there are other developments and improvements.

The company launched a new AI platform which can automatically distinguish sub-types lung cancer pathology and improves on that ability, from PR:

Derived from deep-learning models, together, the findings demonstrate a novel AI-based method for subtyping lung cancer pathologies which impacts treatment options for patients and improved methods of identifying tumor infiltrating white cells found elevated in lung cancer.

Accurately identifying and quantifying tumor-infiltrating white cells is extremely important for prognosis and treatment decisions in this era of personalized medicine, yet it currently requires manual review of whole slide images by medically trained pathologists, and incurs significant delays and cost, explains Dr. Patrick Soon-Shiong, MD, Chairman and CEO of NantHealth.

And they are working on a similar solution for breast cancer. In principle, their TMB (tumor mutational burden) test capability is a generic capability with wide application scope, here is a description of the mechanics from company PR:

Omics Core reports a cancer patient's overall TMB by sequencing and comparing 19,396 protein-coding genes targeting 39 million base pairs of the human genome from a tumor sample and a normal sample, typically from blood or mucosal membrane. TMB indicates the sum of all acquired gene-coding mutations in a tumor genome and is increasingly used to predict response to therapy and identify tumors that could benefit from immunotherapy. In addition, the test reports somatic mutations in 468 cancer-relevant genes accurate to 2% allele frequency, to inform clinical decisions about patient treatment. "Tumor mutation burden ... is now recognized as a key biomarker across multiple tumor types," said Patrick Soon-Shiong, chairman and CEO of Nanthealth. "Studies have shown that immunotherapy treated with high TMB had better outcomes compared to those with low TMB."

And here is a description of a peer reviewed article how this improves targeting capabilities of treatments. It's the more general applicability of TMB and the FDA approval that shareholders are rejoicing.

According to management, two things stand out (PR, our emphasis):

Nanthealth is positioning its tumor-normal test as an advancement over competitors like Myriad Genetics Inc., Color Genomics Inc. and Invitae Corp., which have limited gene panels to look at hereditary risk. By sequencing the whole exome, "we have the ability to identify things that others are missing, and that's particularly critical for drug development," Sandeep Reddy, Nanthealth's chief medical officer, told BioWorld MedTech. "We know about maybe cancer risk, but what do we know about autism or Alzheimer's? By getting that information, that becomes transformative."

As described in that PR, the company's TMB test spots things that other solutions don't, resulting in a more personalized approach to what therapies might be more successful, and it has applicability beyond screening for cancers.

But from a financial point of view, things are also going pretty well.

Data by YCharts

GAAP margins have been trending up and gross margin was much better than a year ago (60% versus 49%), up on product mix (the shift towards its SaaS business).

Operating expenses declined from $20.2M in Q1 2019 to $16.8M in Q1 2020, but $1.1M of that decline is related to the sold Connected Care business.

While cash flow is still negative, there has been tremendous improvement in the last 2.5 years.

Data by YCharts

The net cash burn in Q1 was still around $5M, but this included various closing costs and other front-end loaded costs in relation to the sale of the Connected Care business.

And with that sale the balance sheet has improved a lot, with the company having $47.5M in cash on the books, although the company does have a substantial $95.3M in long-term debt, from the 10-Q:

Data by YCharts

The valuation has jumped along with the share price recently but we think it's still not excessive, it has been much higher in the past on a much more distant promise of monetizing their TMB solutions and in the meantime the company developed a successful SaaS business with their Eviti and NaviNet platforms.

With a backwards looking EV/S of 8X for a company with a unique product that is about to get monetized and a successful SaaS business is high, but not overly so. Analyst still expect EPS losses, $0.23 this year falling to -$0.18 next year, but the company doesn't burn much cash and has plenty of it.

While much is uncertain about the potential of the company's GPS business and the economics of it, the company does have unique capabilities that are likely to become important tools in fighting a number of cancers and the underlying capabilities seem to have wide applicability.

Add to that an attractive SaaS business a declining cash burn and the sale of its Connected Care business providing enough cash to keep the company going for the foreseeable future, and we think we still have an attractive proposition for shareholders, even if it looks like the shares might want to have to digest recent strong gains.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Excerpt from:
NantHealth Points To The Future Of Healthcare - Seeking Alpha

Read More...

Page 19«..10..18192021..3040..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick